Described herein are chimeric antigen receptors (CARs) comprising an extracellular target-binding domain comprising an antibody moiety (e.g., a single chain variable fragment (scFv) antibody), a transmembrane domain, a CD30 costimulatory domain, and a primary signaling domain. Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of cancers (e.g., hematological cancers or solid tumor cancers).